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a b s t r a c t 
Patients with myotonic dystrophy, the most common neuromuscular dystrophy in adults, have a high prevalence of arrhythmic complications with in- 
creased cardiovascular mortality and high risk for sudden death. Sudden death prevention is central and relies on annual follow-up and prophylactic 
permanent pacing in patients with conduction defects on electrocardiogram and/or infrahisian blocks on electrophysiological study. Implantable cardiac 
deﬁbrillator therapy may be indicated in patients with ventricular tachyarrhythmia. 
© 2019 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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1ntroduction 
Myotonic dystrophies are autosomal dominant multi-system
isorders that were ﬁrst recognized as a clinical entity more than
 century ago. Myotonic dystrophies are the most common my-
pathies presenting in adulthood. They are characterized by my-
tonia and progressive muscle degeneration leading to disabling
eakness and wasting. Their combined prevalence is estimated to
e 1 in 80 0 0 persons (12.5/10 0,0 0 0 persons) based on clinical di-
gnoses [1] . Myotonic dystrophies are classiﬁed into type 1 (DM1,
lso known Steinert disease) and type 2 disease (DM2, proximal
yotonic myopathy, or proximal myotonic dystrophy). DM1 is as-
ociated with the abnormal expansion of a CTG trinucleotide re-
eat in the DMPK gene on chromosome 19q13.3 [2] , while DM2, a
ess common disorder that was described more recently, is associa-
ed with a CCTG repeat in the ZNF9 gene on chromosome 3q21 [3] .
Patients with DM1 have a reduced life expectancy mainly due
o respiratory involvement and sudden death. This review aims to
rovide insights into the cardiac manifestations of DM1, the impact
f these manifestations on patient prognosis, and the molecular
athomechanisms underlying DM1 and speciﬁcally the cardiac in-
olvement in DM1, in order to facilitate the development of strate-
ies for the clinical management of patients with DM1. 
olecular genetics and pathomechanisms 
M1 mutation 
The genetic mutation responsible for the autosomal dominant
M1 is an expanded CTGn repeat in the 3 ʹ untranslated region of Conﬂict of interests: None. 
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Please cite this article as: K. Wahbi and D. Furling, Cardiovascular 
Medicine, https://doi.org/10.1016/j.tcm.2019.06.001 he DMPK gene [2] . This CTG tract ranges from 5 to 37 repeats in
ealthy individuals, whereas it ranges from 51 to several thousands
f repeats in DM1 patients. Repeat lengths of 38–50 are considered
 protomutation allele. Globally, the size of the CTG expansion cor-
elates with disease severity and age of onset [4] . This microsatel-
ite expansion is unstable at both the somatic and intergenerational
evels. That is to say, the size of the expanded CTG tract increases
uring the patient’s lifetime as well as over successive generations.
issues in which the CTG expansion is larger are more severely af-
ected, such as the skeletal muscles, heart, and brain [5] , and the
ncrease in CTG expansion size with each successive generation re-
ults in pronounced anticipation. 
NA toxicity and aberrant splicing 
At the molecular level, both the wild-type and mutant DMPK
llele are transcribed; however, mutant DMPK transcripts contain-
ng expanded CUG repeats are not exported to the cytoplasm but
ather retained in the nucleus as discrete aggregates or foci, lead-
ng to DMPK haploinsuﬃciency [6] . This reduction in the levels of
MPK, a serine–threonine protein kinase, was found to have no
ajor phenotypic impact, especially on cardiac or muscle function,
n adult mice, conﬁrming that haploinsuﬃciency is not a key factor
n DM1 pathogenesis [7] . 
A growing body of evidence shows that the triplet repeat ex-
ansion in DM1 leads to a toxic RNA gain-of-function mechanism.
he expanded CUG repeats alter the function of RNA-binding
roteins, and consequently, alter a number of heterologous RNA
argets and pathways in a tissue-speciﬁc manner. Nuclear-retained
UG-expanded transcripts sequester MBNL proteins, which regu-
ate developmental alternative splicing and polyadenylation events,
articularly during the transition of a subset of gene products
rom the fetal to the adult isoforms [8] . Thus, the functional loss
f MBNL results in the re-expression of fetal isoforms in adultnder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Fig. 1. Molecular genetics and pathomechanisms of myotonic dystrophy type 1. 
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a  tissues. This mechanism is reinforced by CELF1 upregulation in
DM1 tissues, as MBNL1 and CELF1 act antagonistically in the
regulation of several splicing events and mRNA expression [9] .
For example, myotonia has been associated with the aberrant
MBNL1-dependent splicing of CLCN1 exon 7a, resulting in the
inclusion of a premature termination codon and reduced levels of
the skeletal muscle-speciﬁc chloride channel CLCN1 [10] . Several
other splicing events in INSR, BIN1, CACNA1S , and DMD pre-mRNAs
that are also regulated by MBNL1 have been associated with
insulin resistance, muscle weakness, and dystrophies. Although
DM1 is often considered a “spliceopathy,” additional mechanisms
may contribute to the development of this complex disease. 
Cardiac involvement: SCN5A missplicing and other mechanisms 
In accordance with functional loss of MBNL proteins due
to their sequestration by expanded CUG repeats, Mbnl deﬁcient
mouse models recapitulate cardinal DM1 cardiac defects and dis-
play several splicing changes including events affecting sodium and
calcium channels [11,12] . Abnormal sodium current properties were
also correlated with conduction defects in a mouse model the hu-
man DMPK gene with expanded CTG repeats and misregulation
of SCN5A mRNA splicing was identiﬁed in heart samples of DM1
patients by RNAseq [13] . SCN5A gene encodes Na v 1.5, the alpha-
subunit of the cardiac voltage-gated sodium channel that is re-
sponsible for the rapid depolarization of cardiac cells and is in-
volved in the cardiac action potential duration as well as the prop-
agation of the impulse throughout the myocardium. The loss of
Na v 1.5 function results in arrhythmic disorders, such as autosomal
dominant conduction system disease and Brugada syndrome [14] . 
In DM1, aberrant splicing of the mutually exclusive 6A/B exons
within SCN5A pre-mRNA leads to a switch from the adult exon 6B
towards the fetal exon 6A, resulting in the re-expression of fetal
Na v 1.5 that has lower excitability than the adult isoform ( Fig. 1 ).
To determine its functional impact, the DM1 missplicing of en-
dogenous Scn5a pre-mRNA was reproduced in the heart tissue of
wild-type adult mice using an AAV-U7 snRNA antisense systemPlease cite this article as: K. Wahbi and D. Furling, Cardiovascular 
Medicine, https://doi.org/10.1016/j.tcm.2019.06.001 13] . These Scn5a -skipped mice re-expressed approximately 30% fe-
al exon 6A and developed conduction system disease with marked
R-interval prolongation, increased QRS duration, supraventricu-
ar arrhythmias, and sudden death in 20% of cases. Involvement
f SCN5A missplicing as a prominent mechanism underlying car-
iac electrical abnormalities in DM1 was reinforced recently by
 CRISPR/Cas9 approach allowing the re-expression of fetal Scn5a
soform in adult mice [15] . 
Several additional mechanisms could contribute to the cardiac
nvolvement in DM1. Thus, CELF1 upregulation due to the abnor-
al activation of the PKC signaling pathway was identiﬁed in a
eart-speciﬁc mouse model expressing interrupted 960CTG repeats
nd displaying dilated cardiomyopathy and arrhythmia [16] . In ad-
ition, altered expression of 22 microRNAs, mainly direct MEF2
ranscriptional targets, were identiﬁed in this mouse model and
alidated in heart samples from DM1 patients [17] . Among them,
t was proposed that (i) the altered expression of miR-21, miR-
9, miR-30, and miR-133, which regulate a network of genes as-
ociated with ﬁbrosis, could contribute to interstitial cardiac ﬁ-
rosis in DM1 patients, and (ii) reduced miR-1 expression could
ontribute to conduction defects, as low miR-1 levels were cor-
elated with cardiac abnormalities and arrhythmias in transgenic
ice [18] . Moreover, miR-1 biogenesis is regulated by MBNL1, and
he loss of MBNL1 function observed in DM1 results in miR-1
ownregulation and increased levels of miR-1 targets such as GJA1
ap-junction proteins and CACNA1C calcium channels, which could
lso contribute to cardiac dysfunctions [19] . 
eneral clinical manifestations 
linical phenotypes 
DM1 has four distinct clinical phenotypes depending on the age
t onset and global disease severity: the adult-onset, congenital,
hildhood-onset, and late-onset oligosymptomatic forms [1] . Glob-
lly, disease severity correlates with mutation size: > 100 repeats
re usually present in patients with adult-onset disease; > 10 0 0 re-manifestations of myotonic dystrophy, Trends in Cardiovascular 
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Table 1 
Clinical manifestations of myotonic dystrophy type 1. 
Skeletal muscle Muscle weakness 
Myotonia 
Digestive Dysphagia 
Constipation 
Diarrhea 
Anal incontinence 
Gallbladder disorders 
Respiratory Respiratory insuﬃciency 
Aspiration pneumonia 
Brain Neuropsychological 
Daytime sleepiness 
Cardiac Conduction system disease 
Supraventricular and ventricular arrhythmias 
Left ventricular systolic dysfunction 
Ocular Cataract (posterior, iridescent, subcapsular opacities) 
Endocrinal Diabetes 
Hypothyroidism 
Hypogonadism, infertility 
Others Frontal balding 
p  
o
 
d  
n  
l  
[  
C  
b  
t  
m  
i
P
 
a  
d  
t  
A  
w  
f  
d  
i  
d  
(  
[
C
 
i  
s  
d  
n  
d
C
 
d  
p  
d  
d  
T  
o  
a  
d  
i  
l  
s  
t  
t  
m  
n  
m  
c  
n
 
s  
o  
i  
d  
s
C
 
i  
d  
a  
s  
e  
r  
(  
E
8  
1  
a  
t  
I  
a  
d  
6  eats, in patients with congenital disease; and 51–100 repeats, in
ligosymptomatic patients. 
Adult-onset disease, the most prevalent form, usually presents
uring the 2nd-to-4th decade of life with muscle weakness, myoto-
ia, and/or cataract. Progression of skeletal muscle weakness can
ead to severe disability, respiratory insuﬃciency, and dysphagia
1] . The other clinical manifestations are summarized in Table 1 .
ongenital DM1 is a severe developmental disorder characterized
y reduced fetal movements, polyhydramnios, severe global hypo-
onia, and respiratory failure at birth. In the childhood-onset form,
ental retardation and learning diﬃculties precede the other man-
festations. 
rognosis 
Life expectancy is greatly shortened in DM1 patients due to
n increased risk of respiratory complications and sudden cardiac
eath, which were the primary causes of death in 33% and 31% pa-
ients, respectively, in the largest cohort published to date [20,21] .
 risk-prediction score to estimate long-term survival probability
as recently developed based on the following: age, diabetes, need
or support when walking, heart rate, systolic blood pressure, ﬁrst-
egree atrioventricular and bundle branch blocks, and vital capac-
ty. This score can be helpful to estimate the competing risk of
eath when pacemakers or implantable cardioverter deﬁbrillators
ICDs) are considered for the primary prevention of sudden death
21] . 
ardiovascular manifestations 
The prevalence of the cardiac manifestations of DM1 is shown
n Table 2 . Most manifestations are arrhythmic and can lead toTable 2 
Prevalence of cardiac manifestations of myotonic dystr
Groh et al. [
( n = 406) 
Age, years 42.3 
Male sex 50.7% 
Conduction system disease 
First-degree atrioventricular block 45.0% 
QRS > 120 ms 16.5% 
Atrial ﬁbrillation/ﬂutter 12.8% 
Ventricular arrhythmias 1.9% 
Left ventricular dysfunction 11.3% 
Please cite this article as: K. Wahbi and D. Furling, Cardiovascular 
Medicine, https://doi.org/10.1016/j.tcm.2019.06.001 udden death. Cardiac ﬁbrosis and fatty inﬁltration affect the car-
iac conduction system at all levels (sinoatrial and atrioventricular
odes, His–Purkinje system), providing a substrate for conduction
efects, ectopic activity, and re-entrant arrhythmias. 
ardiovascular mortality 
Among the cardiovascular causes of death in DM1 patients, sud-
en cardiac death is the most frequent (43% patients), followed by
ulmonary embolism (25%), terminal heart failure (17%), myocar-
ial infarction (5%), and ischemic stroke (3%) [21] . The annual inci-
ence of sudden death has been estimated at 0.53%–1.16% [20–23] .
he progression of conduction system disease to complete atri-
ventricular block and asystole and ventricular tachyarrhythmias
re generally assumed to be the main mechanisms underlying sud-
en death. Advanced atrioventricular block has been documented
n 12% patients at 10 years of follow-up in the largest cohort pub-
ished to date [24] . It is noteworthy that mechanisms underlying
udden cardiac death are diﬃcult to determine and remain con-
roversial, especially the proportion of sudden deaths attributable
o major conduction defects or primary ventricular tachyarrhyth-
ias. As DM1 is a complex disease involving multiple systems,
on-cardiac causes can also be involved. For example, massive pul-
onary embolism has been suspected or identiﬁed at autopsy in
ases of sudden death after ICD or pacemaker implantation with
o record of ventricular arrhythmias in the implanted device [24] . 
Independent predictors of sudden death are (i) clinical diagno-
is of atrial tachyarrhythmia and electrocardiogram (ECG) with one
f the following features: any rhythm other than sinus rhythm, PR
nterval ≥ 240 ms, QRS duration ≥ 120 ms, and second- or third-
egree atrioventricular block [20] , and (ii) age, family history of
udden death, and left bundle branch block [25] . 
onduction system disease 
Conduction system disease is the most prevalent cardiac man-
festation of DM1. First-degree atrioventricular, fascicular, or bun-
le branch blocks have been identiﬁed in 28%–45% patients at di-
gnosis [20–23] . Most patients with mild conduction defects on
urface ECG are found to have infrahisian conduction defects on
lectrophysiological studies, with the HV interval signiﬁcantly cor-
elated with PR interval ( r = 0.34, P = 0.002) and QRS widening
 r = 0.42, P = 0.0 0 01) [25] . Moreover, among patients with normal
CG ﬁndings, 55% had infrahisian conduction defects (HV = 60–
0 ms). Progression to complete atrioventricular block occurred in
9% patients in a large cohort of unselected DM1 patients during
 12-year follow-up (median age, 50 years) [24] and in 55% pa-
ients with HV interval ≥ 70 ms during a 55 months follow-up [26] .
ndependent predictors of advanced atrioventricular block include
ge, male sex, atrial ﬁbrillation, syncope, and evidence of any con-
uction defect on ECG [24] . In another multicenter registry where
2 patients out of 406 were implanted with pacemakers, mostlyophy type 1. 
16] Wahbi et al. [17] 
( n = 914) 
Petri et al. [20] 
( n = 1828) 
38.4 –
47.0% –
34.1% 28.2% 
18.4% 19.9% 
7.6% 5.0% 
1.0% –
8.4% 7.2% 
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t  prophylactically for ECG conduction abnormalities, 17 (27.4%) were
pacemaker-dependent at last follow-up [25] . 
Supraventricular arrhythmias 
Supraventricular arrhythmias, including atrial ﬁbrillation, ﬂut-
ter, and tachycardia, are present in 5%–12% patients at presen-
tation [20–23] . Supraventricular arrhythmias usually occur in pa-
tients without signiﬁcant atrial remodeling. Rapid atrial ﬁbrillation
can manifest as lightheadedness and syncope in young patients
and be the ﬁrst sign of disease [28] . The risk of arterial throm-
boembolism in patients with supraventricular arrhythmias remains
unknown, but several cases of stroke have been reported among
patients with CHADS-VASC scores of 0 [29] . 
Increased P wave duration and dispersion and echocardio-
graphic atrial electromechanical delay (intra-left and inter-atrial)
are common in DM1 patients and are associated with presence or
further development of atrial ﬁbrillation [30,31] . 
Ventricular arrhythmias 
Re-entry circuits promoted by ﬁbrotic foci, fatty inﬁltration, and
delayed conduction in the His–Purkinje system along with bundle
branch re-entry tachycardia [32] may lead to ventricular arrhyth-
mias. The exact prevalence of premature ventricular contractions
in DM1 has not been established in large cohort studies with sys-
tematic Holter ECG; however, a meta-analysis of published cases
suggested a prevalence of 14% [23] . In the largest cohort published
to date, the prevalence rates of non-sustained and sustained ven-
tricular tachycardia were 2.2% and 0.8%, respectively [24] . The inci-
dence of sustained ventricular tachycardia was 2.3% in a large co-
hort of unselected DM1 patients during a 12-year follow-up and
non-sustained ventricular tachycardia was the only independent
predictor of sustained ventricular tachycardia [24] . The prognos-
tic implications of inducible ventricular tachycardia during electro-
physiological studies is uncertain in this patient population. 
Several studies have shown evidence of increased disper-
sion of ventricular repolarization (QTc dispersion, JTc dispersion,
transmural dispersion of repolarization, QT variability index) and
sympatho-vagal balance in patients with DM1 (Heart Rate Vari-
ability) suggesting a potential interest of these measures to predict
ventricular arrhythmias [33–35] . 
Venous thromboembolism 
Venous thromboembolism, deﬁned as deep vein thrombosis
and/or pulmonary embolism, occurred in 10.3% of 1148 DM1 pa-
tients over a 10-year follow-up [36] . Furthermore, 58% patients
who developed thromboembolism had no predisposing factors. The
standardized rate ratio for venous thromboembolism was 7.5 be-
tween this cohort and an age- and sex-matched community-based
population. The risk of venous thromboembolism was 5.5 higher
than that in patients with other inherited myopathies, after adjust-
ments for potential confounding factors. These observations indi-
cate that a systematic venous thromboembolism prophylaxis that
can be applied in any medical or surgical setting is required. Ve-
nous thromboembolism in DM1 may be attributable to complex
pathogenic mechanisms such as altered mRNA processing of coag-
ulation factors. The following predict venous thromboembolism in
DM1: older age, history of venous thromboembolism, obesity, Wal-
ton score, cancer, conduction disease, and ambulation loss. 
Other manifestations 
Arterial systolic hypotension 
Systolic blood pressure ≤ 110 mmHg occurs in 24% patients and
is independently associated with greater all-cause mortality [21] . ItPlease cite this article as: K. Wahbi and D. Furling, Cardiovascular 
Medicine, https://doi.org/10.1016/j.tcm.2019.06.001 s unclear whether systolic hypotension is a speciﬁc complication
f the disease or a non-speciﬁc marker of disease severity. 
leep apnea 
Sleep apnea is a common, multifactorial complication that pre-
ipitates both atrial and ventricular tachyarrhythmias [37] . The ef-
ect of nocturnal mechanical ventilation on arrhythmias in DM1 is
ot known. 
yocardial dysfunction 
Left ventricular dysfunction occurs in 7.2%–11.3% patients
18–20] and remains asymptomatic in most patients. Subclinical
yocardial systolic dysfunction can be detected using strain rate
maging echocardiography [38] and correlates with conduction
ystem disease. Reduced global and regional coronary ﬂow reserve
s demonstrable with positron emission tomography with oxygen-
abeled water, but its clinical implications remain unknown [39] . 
itral valve prolapse 
Mitral valve prolapse is associated with DM1 [40] , but its preva-
ence has not been estimated in large prospective cohorts, and se-
ere mitral regurgitation is rare in DM1. 
enotype–phenotype correlations 
The size of the CTG ampliﬁcation correlates signiﬁcantly with
he severity of cardiac involvement (conduction defects on ECG
nd left ventricular systolic dysfunction), major conduction defects,
nd sudden death [41] , even adjusting for confounders such as age,
ender, and diabetes mellitus. However, all DM1 patients, includ-
ng those with CTG ampliﬁcations < 100 repeats, are at risk for
ife-threatening complications. 
ardiac clinical investigations 
isk stratiﬁcation for sudden death 
The prevention of sudden death is central to the management
f DM1 patients, and the main objective of cardiac diagnostic
orkup is risk stratiﬁcation. Two main approaches—invasive and
on-invasive—are used to identify high-risk patients who require
n implantable device. 
on-invasive approach 
This is based on 12-lead ECG and 24-h ambulatory ECG. The
ombination of any cardiac rhythm other than sinus rhythm, PR
nterval ≥ 240 ms, QRS duration ≥120 ms, and second- or third-
egree atrioventricular block [20] is independently associated with
udden death. The sensitivity, speciﬁcity, and positive and nega-
ive predictive values of these criteria were 74.1%, 61.7%, 12.1%, and
7.1%, respectively. 
nvasive approach 
This is based on 12-lead ECG and electrophysiology study in pa-
ients with mild conduction defects on ECG. Patients with HV in-
erval ≥ 70 ms [22,26,27] are at a high risk for complete atrioven-
ricular block and sudden death. In a prospective study including
9 patients with HV interval ≥ 70 ms who underwent pacemaker
mplantation, 51% had advanced atrioventricular blocks stored in
heir device memory. 
The accuracy of these two approaches in the prediction of sud-
en death and/or advanced atrioventricular block has been stud-
ed in different populations, but no direct comparison has yet
een performed. Current data suggest that the invasive strategy
as greater positive predictive value, but its speciﬁcity and nega-
ive predictive values are not known. Prophylactic pacing with pa-
ient selection based on the invasive approach reduces the risk ofmanifestations of myotonic dystrophy, Trends in Cardiovascular 
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tudden death in observational, non-randomized studies (see para-
raph on cardiac treatments); [22] the potential clinical beneﬁt of
acing using the non-invasive criteria is unknown. 
ther investigations 
Cardiac workup in DM1 is also used for the early detection of
ther cardiac manifestations such as supraventricular tachyarrhyth-
ias and left ventricular dysfunction, which may be present even
n asymptomatic patients [24] . 
ecommendations for cardiac workup 
Annual follow-up is recommended in DM1 patients, includ-
ng asymptomatic patients. Considering the prognostic implica-
ions and complexity of the cardiac involvement in DM1, follow-up
hould be undertaken by a cardiologist with experience in manag-
ng DM1 patients. The cardiac workup should include 12-lead ECG
t diagnosis and at least yearly thereafter. Patients with cardiac
ymptoms, conduction block on ECG, and/or supraventricular or
entricular arrhythmias should also undergo echocardiogram and
4-h ambulatory ECG. 
Electrophysiological study can be useful in patients with cardiac
ymptoms or conduction disease, such as ﬁrst-degree atrioventric-
lar, fascicular, and bundle branch block, on ECG. It may be re-
eated in patients who develop symptoms or show progression of
onduction disease on the follow-up ECG [42] . 
ardiac treatments 
udden death prevention: pacing and deﬁbrillator implantation 
Pacing therapy is the ﬁrst-line treatment for sudden death pre-
ention in DM1 [43] and an ICD may be considered to minimize
he risk of sudden death from VT if meaningful survival of greater
han 1 year is expected. Prophylactic pacing is recommended in
atients with conduction system disease due to the risk of rapid
npredictable progression to complete atrioventricular block. No
andomized trial has assessed the prognostic impact of prophylac-
ic pacing yet. However, propensity-score analysis of data from a
arge registry with 900 DM1 patients showed signiﬁcantly greater
verall survival (hazard ratio, 0.47–0.61) among patients with mild
onduction defects on ECG who underwent electrophysiological
tudy and permanent pacing if the HV interval ≥ 70 ms rather than
ollow-up ECG and ambulatory ECG assessment [22] . This beneﬁt
as largely attributable to a lower incidence of sudden death (haz-
rd ratio, 0.24–0.28). 
In DM1 patients, permanent pacing 
- is recommended in the presence of symptomatic or asymp-
tomatic third-degree or advanced second-degree atrioventricu-
lar block. 
- may be considered in patients with ﬁrst-degree atrioventricu-
lar, fascicular, or bundle branch block. (Thresholds values of 240
and 120 ms for PR interval and QRS duration, respectively, may
represent a good compromise in terms of sensitivity and speci-
ﬁcity.) 
- may be considered in patients with HV interval ≥ 70 ms on
electrophysiological study, regardless of symptoms. 
ICDs can be considered to minimize the risk of sudden death
rom VT if meaningful survival of greater than 1 year is expected
nd more speciﬁcally in patients with the following indications: 
- sustained ventricular tachyarrhythmias (for secondary preven-
tion), 
- the same indications as in non-ischemic dilated cardiomyopa-
thy (for primary prevention), Please cite this article as: K. Wahbi and D. Furling, Cardiovascular 
Medicine, https://doi.org/10.1016/j.tcm.2019.06.001 - any indication for permanent pacing along with non-sustained
ventricular tachycardia on ambulatory ECG or sustained ventric-
ular tachycardia induced by programmed ventricular stimula-
tion. 
Prophylactic pacemaker/ICD is considered if the life expectancy
xceeds 1 year. Additionally, the high risk of competing causes of
eath such as respiratory failure should be taken into account [19] .
ultidisciplinary evaluation of global disease severity is warranted
nd should include an estimation of survival probability using a
peciﬁc survival score [21] . 
Atrial pacing in the Bachmann bundle region was associated
ith a reduction of atrial electromechanical delay and the risk of
-wave oversensing on the atrial lead, compared with right atrial
timulation, but showed no beneﬁt for the prevention of atrial ﬁb-
illation [44–46] . 
upraventricular arrhythmias 
It remains unclear whether DM1 patients with atrial ﬁbrilla-
ion or other atrial arrhythmias should be treated similarly to pa-
ients from the general population. Given the lack of data on the
isk of thromboembolic complications in DM1, the indications for
nticoagulation should probably be the same as in the general
opulation. Preliminary data suggest that class I antiarrhythmic
rugs should be used very cautiously or be contraindicated in pa-
ients with conduction system disease or a history of ventricular or
upraventricular arrhythmias owing to the ventricular arrhythmo-
enic effects of these drugs. The eﬃcacy of radiofrequency ablation
ppears to be similar to that reported in the general population
or the prevention of atrial ﬂutter recurrence [29] , but remains un-
nown for atrial ﬁbrillation. Minimal ventricular pacing has been
hown to be an eﬃcient strategy to reduce the risk of atrial ﬁb-
illation in DM1 patients implanted with a pacemaker [47] . An in-
rease of the incidence of paroxysmal atrial ﬁbrillation has been
hown in patients with a higher rate of right ventricular pacing
nd a lower rate of atrial stimulation [48] . 
eft ventricular dysfunction and heart failure therapy 
The management of heart failure in DM1 should follow cur-
ent American College of Cardiology/American Heart Association
uidelines. The uptitration of angiotensin-converting enzyme (ACE)
nhibitors and angiotensin receptor blockers is often diﬃcult be-
ause many patients develop symptomatic hypotension. Hyper-
alemia is a frequent complication of ACE inhibitors and aldos-
erone antagonists in these patients even when renal function is
reserved. 
enous thromboembolism 
More systematic venous thromboembolism prophylaxis and 
reatments should be offered to patients with DM1 than usually
ispensed [27] . The most appropriate management strategy for ve-
ous thromboembolism in DM1 remains to be deﬁned and should
robably be similar to that in patients with inherited throm-
ophilic diseases, such as protein C or protein S deﬁciency. The
ecision to initiate prolonged curative anticoagulation in patients
ith venous thromboembolism is diﬃcult, as the risk of bleeding
omplications may be high in this population who are at an in-
reased risk of falls and whose compliance with treatment might
e variable. In women, careful counseling on the use of oral con-
raceptives and postmenopausal estrogen replacement therapy is
equired since the risk of venous thromboembolism is highest be-
ween 20 and 59 years of age [29] . manifestations of myotonic dystrophy, Trends in Cardiovascular 
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 Class I antiarrhythmic drugs safety 
Some concerns have been raised regarding the safety of class I
antiarrhythmic drugs in DM1 patients. The indications for mexile-
tine are frequently discussed in DM1 patients, as this drug is the
most eﬃcient treatment for myotonia. The use of these medica-
tions may exacerbate the loss of cardiac sodium channel function,
which contributes to the development of cardiac arrhythmias [49] .
Several case series have shown that intravenous ﬂecainide or aj-
maline can trigger severe ventricular tachyarrhythmias or unmask
a type 1 Brugada pattern in DM1 patients [50] . Therefore, these
drugs should be used very cautiously, and their risk-beneﬁt ratio
should be assessed on an individual basis. 
Speciﬁc populations 
Pediatric patients 
The prevalence of cardiac involvement and the risk of ad-
verse events have not been estimated in large pediatric popula-
tions with DM. However, several case reports have shown that
pediatric DM1 patients can present with atrial arrhythmias and
less commonly with sustained ventricular tachyarrhythmias, which
may cause sudden death [51] . These events have been exclusively
reported after the age of 10 years and were triggered in most cases
by exercise. Complete atrioventricular block has not yet been re-
ported in DM1 patients before the age of 18 years. A Danish na-
tionwide study showed that pediatric DM patients had a higher
prevalence of heart disease than the general population, with a
standardized incidence ratio of 19.4 (95% CI, 4.92–52.7) [52] . 
These data suggest that the early detection of cardiac involve-
ment should be considered after the age of 10 years, particularly in
patients who practice sports. Indications for 12-lead ECG, echocar-
diography, and ambulatory ECG should probably be the same as in
adults. 
Myotonic dystrophy type 2 
Patients with DM2 present with similar cardiac manifestations
as patients with DM1, but with a lower prevalence and later age of
onset [53,54] . Complete atrioventricular block occurs in most pa-
tients in their 70 s. A higher proportion of patients develop left
ventricular dysfunction and ischemic stroke, particularly, patients
with atrial ﬁbrillation. The risk of sudden death is lower in DM2
patients than in DM1 patients [55] . DM2 patients may beneﬁt from
the same approach for risk stratiﬁcation and preventive treatments
for sudden death as in DM1 patients. 
Future directions 
There is an unmet need for research on risk stratiﬁcation in
DM1 and DM2 to improve the criteria for prophylactic permanent
pacing and ICD therapy. The accuracy of non-invasive workup ver-
sus electrophysiological study should be compared in large popu-
lations. Considering the high risk of sudden death, randomized tri-
als to assess the impact of preventive measures on prognosis are
hardly feasible; therefore, analysis of large multicenter registries
will be of great importance. 
Supplementary materials 
Supplementary material associated with this article can be
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